Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 14, 2023 | Press Releases

– RECOVER global Phase 3 trial successfully met all primary and secondary endpoints with statistically significant and clinically meaningful reductions across all major symptom domains at week 4 with 50 mg of brilaroxazine vs. placebo in schizophrenia –...

Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Oct 30, 2023 | Press Releases

– Successfully met primary endpoint; brilaroxazine 50 mg delivered a statistically significant and clinically meaningful 10.1-point reduction in Positive and Negative Syndrome Scale (PANSS) total score vs. placebo at week 4, p<0.001 – –...

Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

Sep 25, 2023 | Press Releases

Topline data for RECOVER trial on track for October 2023CUPERTINO, Calif., Sept. 25, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that...

Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023 | Press Releases

CUPERTINO, Calif., Sept. 07, 2023 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

Aug 17, 2023 | Press Releases

– 402 patients completed enrollment across multiple sites in the US, Europe, and Asia – – Topline data for Phase 3 RECOVER study expected in October 2023 – – Completion of 1-year open-label extension clinical study expected in Q3 2024...